Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ.

Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.

2.

LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions.

Jepson S, Vought B, Gross CH, Gan L, Austen D, Frantz JD, Zwahlen J, Lowe D, Markland W, Krauss R.

J Biol Chem. 2012 Jun 22;287(26):22184-95. doi: 10.1074/jbc.M112.366179. Epub 2012 Apr 18.

3.

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Markland W, Namchuk MN, Nanthakumar S, Poondru S, Straub J, ter Haar E, Xie X.

J Med Chem. 2009 Oct 22;52(20):6362-8. doi: 10.1021/jm900630q.

PMID:
19827834
4.

Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).

Farmer LJ, Bemis G, Britt SD, Cochran J, Connors M, Harrington EM, Hoock T, Markland W, Nanthakumar S, Taslimi P, Ter Haar E, Wang J, Zhaveri D, Salituro FG.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6231-5. doi: 10.1016/j.bmcl.2008.09.106. Epub 2008 Oct 7.

PMID:
18938080
5.

Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.

Gross CH, Parsons JD, Grossman TH, Charifson PS, Bellon S, Jernee J, Dwyer M, Chambers SP, Markland W, Botfield M, Raybuck SA.

Antimicrob Agents Chemother. 2003 Mar;47(3):1037-46.

8.

Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.

Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, Caron PR, Wilson KP, Su MS.

Structure. 1998 Aug 15;6(8):983-91.

9.

Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae.

Markland W, Petrillo RA, Fitzgibbon M, Fox T, McCarrick R, McQuaid T, Fulghum JR, Chen W, Fleming MA, Thomson JA, Chambers SP.

J Gen Virol. 1997 Jan;78 ( Pt 1):39-43.

PMID:
9010283
10.

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA.

Cell. 1996 Oct 18;87(2):343-55. Erratum in: Cell 1997 Apr 4;89(1):159.

11.
12.
13.

Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin.

Markland W, Ley AC, Lee SW, Ladner RC.

Biochemistry. 1996 Jun 18;35(24):8045-57.

PMID:
8672509
14.

Affinity maturation of proteins displayed on surface of M13 bacteriophage as major coat protein fusions.

Roberts BL, Markland W, Ladner RC.

Methods Enzymol. 1996;267:68-82.

PMID:
8743310
15.

Selection for protease inhibitors using bacteriophage display.

Markland W, Roberts BL, Ladner RC.

Methods Enzymol. 1996;267:28-51. No abstract available.

PMID:
8743308
16.

M13 bacteriophage displaying disulfide-constrained microproteins.

McLafferty MA, Kent RB, Ladner RC, Markland W.

Gene. 1993 Jun 15;128(1):29-36. Review.

PMID:
8508957
17.

Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors.

Roberts BL, Markland W, Siranosian K, Saxena MJ, Guterman SK, Ladner RC.

Gene. 1992 Nov 2;121(1):9-15.

PMID:
1385268
18.

Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage.

Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, Ladner RC.

Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2429-33.

19.

Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13.

Markland W, Roberts BL, Saxena MJ, Guterman SK, Ladner RC.

Gene. 1991 Dec 20;109(1):13-9.

PMID:
1721885
20.

Association of p62c-yes with polyomavirus middle T-antigen mutants correlates with transforming ability.

Kornbluth S, Cheng SH, Markland W, Fukui Y, Hanafusa H.

J Virol. 1990 Apr;64(4):1584-9.

21.

Tissue-type plasminogen activator variants with domain duplications and rearrangements.

Markland W, Pollock D, Livingston DJ.

Protein Eng. 1989 Nov;3(2):111-6.

PMID:
2556697
22.
23.
24.

Mutants of polyomavirus middle-T antigen.

Markland W, Smith AE.

Biochim Biophys Acta. 1987 Nov 25;907(3):299-321. Review.

PMID:
3315000
26.

Site-directed mutagenesis of polyomavirus middle-T antigen sequences encoding tyrosine 315 and tyrosine 250.

Markland W, Oostra BA, Harvey R, Markham AF, Colledge WH, Smith AE.

J Virol. 1986 Aug;59(2):384-91.

27.

In vitro mutagenesis of the putative membrane-binding domain of polyomavirus middle-T antigen.

Markland W, Cheng SH, Oostra BA, Smith AE.

J Virol. 1986 Jul;59(1):82-9.

29.

Supplemental Content

Loading ...
Support Center